Bamco Inc. NY Makes New $3.54 Million Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

Bamco Inc. NY bought a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 31,000 shares of the company's stock, valued at approximately $3,542,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Maverick Capital Ltd. raised its position in Vaxcyte by 41.9% in the third quarter. Maverick Capital Ltd. now owns 976,249 shares of the company's stock valued at $111,556,000 after purchasing an additional 288,341 shares during the period. Verition Fund Management LLC acquired a new stake in shares of Vaxcyte in the third quarter valued at $489,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Vaxcyte by 38.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 408,274 shares of the company's stock valued at $46,653,000 after buying an additional 112,512 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Vaxcyte by 4.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,311 shares of the company's stock valued at $2,435,000 after buying an additional 826 shares in the last quarter. Finally, Acuta Capital Partners LLC grew its stake in shares of Vaxcyte by 22.6% in the third quarter. Acuta Capital Partners LLC now owns 135,400 shares of the company's stock valued at $15,472,000 after buying an additional 25,000 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.

Vaxcyte Stock Performance

NASDAQ PCVX traded up $2.67 during trading on Wednesday, reaching $93.04. 760,543 shares of the company's stock were exchanged, compared to its average volume of 906,135. The stock has a market cap of $11.60 billion, a P/E ratio of -20.23 and a beta of 0.94. The company has a 50 day moving average price of $104.28 and a two-hundred day moving average price of $90.73. Vaxcyte, Inc. has a 1 year low of $53.26 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.10) by $0.27. During the same period in the previous year, the company earned ($0.91) EPS. Research analysts forecast that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. BTIG Research lifted their price objective on Vaxcyte from $98.00 to $160.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Bank of America boosted their target price on Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a research note on Wednesday, September 4th. Jefferies Financial Group boosted their target price on Vaxcyte from $108.00 to $129.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. Finally, Leerink Partners boosted their target price on Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $147.50.

Insiders Place Their Bets

In other news, CEO Grant Pickering sold 15,000 shares of the business's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $92.45, for a total value of $1,386,750.00. Following the completion of the sale, the chief executive officer now directly owns 450,301 shares of the company's stock, valued at approximately $41,630,327.45. The trade was a 3.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew Guggenhime sold 8,000 shares of the company's stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total value of $927,520.00. Following the sale, the chief financial officer now directly owns 90,383 shares of the company's stock, valued at approximately $10,479,005.02. This represents a 8.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 110,464 shares of company stock valued at $11,924,596 in the last ninety days. Insiders own 3.10% of the company's stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.